Annovis Bio, Inc. (ANVS) is a publicly traded Healthcare sector company. As of July 7, 2026, ANVS trades at $2.03 with a market cap of $83.81M and a P/E ratio of -1.42. ANVS moved +1.52% today. Year to date, ANVS is -44.51%; over the trailing twelve months it is -18.64%. Its 52-week range spans $1.11 to $7.52. Analyst consensus is buy with an average price target of $12.50. Rallies surfaces ANVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ANVS insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $2.03 |
| Market Cap | $83.81M |
| P/E Ratio | -1.42 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.52 |
| 52-Week Low | $1.11 |
| Volume | 1.48M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.85M |
| Gross Margin | 0.00% |
2 analysts cover ANVS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.50.